{"id":66888,"date":"2023-05-31T10:27:00","date_gmt":"2023-05-31T13:27:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/66888\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/"},"modified":"2023-05-31T10:27:00","modified_gmt":"2023-05-31T13:27:00","slug":"congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/","title":{"rendered":"Congresso EULAR 2023: AbbVie apresenta dados de longo prazo que confirmam perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe em diferentes doen\u00e7as reum\u00e1ticas"},"content":{"rendered":"<p><b>PR NEWSWIRE<\/b><\/p>\n<div class=\"xn-content\">\n<span class=\"legendSpanClass\">S\u00c3O PAULO<\/span>, <span class=\"legendSpanClass\">31 de maio de 2023<\/span> \/PRNewswire\/ &#8212;\u00a0A AbbVie (NYSE: ABBV) anunciou que ser\u00e3o apresentados novos dados de longo prazo que mostram o perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe, referentes aos estudos SELECT-COMPARE, SELECT-PsA 1 e SELECT-AXIS 2, durante o Congresso Europeu de Reumatologia, EULAR 2023, que acontece de 31 de maio a 3 de junho, em Mil\u00e3o.<\/p>\n<p>&#8220;Estes novos resultados dos programas de estudos cl\u00ednicos SELECT tornam ainda mais robusta a gama de evid\u00eancias dispon\u00edveis para o perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe em v\u00e1rias doen\u00e7as reum\u00e1ticas&#8221;, disse Mudra Kapoor, vice-presidente de Assuntos M\u00e9dicos de Imunologia da AbbVie. &#8220;O nosso investimento em dados de longo prazo \u00e9 uma parte essencial do compromisso cont\u00ednuo da AbbVie para garantir que estamos apoiando pacientes que vivem com doen\u00e7as imunomediadas&#8221;.<\/p>\n<p>Os dados de longo prazo que ser\u00e3o apresentados no Congresso EULAR 2023 incluem mais de 20 desfechos cl\u00ednicos e dados de seguran\u00e7a de aproximadamente 2.450 pacientes representando mais de 6.700 pacientes-ano em artrite reumatoide (AR), artrite psori\u00e1tica (PsA) e espondilite anquilosante (EA)<sup>1,2,3<\/sup>.<\/p>\n<p>&#8220;O impacto das doen\u00e7as reum\u00e1ticas, como artrite reumatoide, artrite psori\u00e1sica e espondilite anquilosante, pode afetar profundamente a qualidade de vida do paciente&#8221;, disse o Dr. <span class=\"xn-person\">Roy Fleischmann<\/span>, investigador do estudo SELECT-COMPARE e professor cl\u00ednico de medicina no Centro M\u00e9dico do Sudoeste da Universidade do <span class=\"xn-location\">Texas<\/span>, e codiretor m\u00e9dico do Centro de Pesquisas Cl\u00ednicas Metroplex.<\/p>\n<p>&#8220;Esses dados de efic\u00e1cia e seguran\u00e7a fornecem informa\u00e7\u00f5es adicionais para ajudar os profissionais de sa\u00fade a fazerem escolhas importantes de tratamento com seus pacientes e destacam a capacidade de manter o controle da doen\u00e7a com tratamento por longo prazo&#8221;, acrescentou o especialista.<\/p>\n<p>Os destaques dos estudos a serem apresentados s\u00e3o:<\/p>\n<ul type=\"disc\">\n<li><u>Seguran\u00e7a e efic\u00e1cia a longo prazo de upadacitinibe ou adalimumabe em pacientes com artrite reumatoide: dados de cinco anos do estudo SELECT-COMPARE <\/u>\u00a0Os resultados do estudo corroboram a efic\u00e1cia a longo prazo e o perfil de seguran\u00e7a de upadacitinibe na popula\u00e7\u00e3o de pacientes estudada<sup>1<\/sup>.<\/li>\n<li><u>Efic\u00e1cia e seguran\u00e7a a longo prazo de upadacitinibe em pacientes com artrite psori\u00e1tica: resultados de tr\u00eas anos do estudo SELECT-PsA 1 de fase 3. <\/u>Os resultados do estudo corroboram o perfil de efic\u00e1cia e seguran\u00e7a de upadacitinibe na popula\u00e7\u00e3o de pacientes estudada ao longo de tr\u00eas anos<sup>2.<\/sup><\/li>\n<li><u>Efic\u00e1cia e seguran\u00e7a de upadacitinibe em pacientes com espondilite anquilosante ativa e resposta inadequada \u00e0 terapia biol\u00f3gica com DMARD: resultados de um ano de um estudo de fase 3 . <\/u>A AbbVie relatou resultados iniciais da semana 14 do estudo SELECT-AXIS 2 AS bDMARD-IR durante o Congresso EULAR 2022.\u00a0<\/li>\n<\/ul>\n<p><b>Sobre upadacitinibe<\/b>\u00a0<\/p>\n<p>Descoberto e desenvolvido por cientistas da AbbVie, upadacitinibe \u00e9 um inibidor seletivo de JAK que est\u00e1 sendo estudado em v\u00e1rias doen\u00e7as inflamat\u00f3rias imunomediadas<sup>4-16<\/sup>.\u00a0 Estudos de upadacitinibe em artrite reumatoide, dermatite at\u00f3pica, artrite psori\u00e1sica, espondiloartrite axial, doen\u00e7a de Crohn, colite ulcerativa, arterite de c\u00e9lulas gigantes, arterite de Takayasu e l\u00fapus erimatoso sist\u00eamico est\u00e3o tamb\u00e9m em desenvolvimento <sup>11,15,18<\/sup>.<\/p>\n<p>No Brasil, upadacinitibe tem indica\u00e7\u00f5es aprovadas para artrite reumatoide, artrite psori\u00e1sica, espondilite anquilosante e dermatite at\u00f3pica e a bula completa pode ser encontrada <a href=\"https:\/\/www.abbvie.com.br\/content\/dam\/abbvie-dotcom\/br\/documents\/Paciente_ANVISA_RINVOQAD.pdf\" target=\"_blank\" rel=\"nofollow noopener\">aqui.<\/a><\/p>\n<p><b>Sobre adalimumabe<sup>17<\/sup><\/b><\/p>\n<p>As indica\u00e7\u00f5es de adalimumabe (anticorpo monoclonal totalmente humano) aprovadas para uso pedi\u00e1trico e adulto, no Brasil, \u00a0podem ser encontradas <a href=\"https:\/\/www.abbvie.com.br\/content\/dam\/abbvie-dotcom\/br\/documents\/Paciente_ANVISA_HUMIRA_AC.pdf\" target=\"_blank\" rel=\"nofollow noopener\">aqui<\/a>.<\/p>\n<p><b>Sobre a AbbVie?\u00a0<\/b><\/p>\n<p>A miss\u00e3o da AbbVie \u00e9 descobrir e fornecer medicamentos inovadores que solucionem as quest\u00f5es s\u00e9rias de sa\u00fade de hoje e enfrentem os desafios m\u00e9dicos de amanh\u00e3. A companhia se empenha em causar um impacto not\u00e1vel na vida das pessoas em \u00e1reas terap\u00eauticas chave: Imunologia, Oncologia, Neuroci\u00eancia, Oftalmologia, Virologia e Gastrenterologia, al\u00e9m dos servi\u00e7os e produtos da Allergan Aesthetics.<\/p>\n<p>No Brasil, a AbbVie come\u00e7ou a operar no in\u00edcio de 2014. Suas unidades de neg\u00f3cios locais incluem Imunologia, Oncologia, Oftalmologia e Neuroci\u00eancia, al\u00e9m dos servi\u00e7os e produtos da Allergan Aesthetics. A AbbVie conta com 34 projetos ativos de Pesquisa e Desenvolvimento, envolvendo mais de 200 centros m\u00e9dicos de todas as regi\u00f5es do pa\u00eds e cerca de 1.000 cientistas brasileiros. Para mais informa\u00e7\u00f5es, acesse <a href=\"https:\/\/nam12.safelinks.protection.outlook.com\/?url=http%3A%2F%2Fwww.abbvie.com.br%2F&amp;data=05%7C01%7Cguilherme.bronzato%40abbvie.com%7C45c6a098a170482e995608dabdd19df6%7C6f4d03de95514ba1a25bdce6f5ab7ace%7C0%7C0%7C638031005235041116%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=97cSgrGumM1Zt6MRweASlQ8cbHKHZUbhGqsvL986ov0%3D&amp;reserved=0\" target=\"_blank\" rel=\"nofollow noopener\">www.abbvie.com.br<\/a> e siga @AbbVie no LinkedIn e @AbbVieBrasil no Instagram.<\/p>\n<p><b><u>Refer\u00eancias<\/u><\/b><\/p>\n<p><sup>1.\u00a0 <\/sup>Fleischmann, R.M., et al. Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data From the SELECT-COMPARE Study. EULAR 2023 Congress; 0849.\u00a0<\/p>\n<p><sup>2.\u00a0 <\/sup>Mcinnes, I., et al. Long-Term Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 3-Year Results from the Phase 3 SELECT-PsA 1 Study. EULAR 2023 Congress; 1541.\u00a0<\/p>\n<p><sup>3.\u00a0 <\/sup>Baraliakos, X., et al. Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis and an Inadequate Response to Biologic DMARD Therapy: One-Year Results from a Phase 3 Study. EULAR 2023 Congress; 1122.\u00a0<\/p>\n<p><sup>4.\u00a0 <\/sup>Upadacitinibe [Resumos das caracteristicas na Europa]. AbbVie Deutschland GmbH &amp; Co KG. Dispon\u00edvel em: www.ema.europa.eu<\/p>\n<p><sup>5.\u00a0 <\/sup>Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.\u00a0<i>The Lancet<\/i>. 2022;399(10341):2113-2128. doi:10.1016\/S0140-6736(22)00581-5.\u00a0<\/p>\n<p><sup>6.\u00a0 <\/sup>Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.\u00a0<i>Annals of the Rheumatic Diseases<\/i>. 2021;80(3):312-320. doi:10.1136\/annrheumdis-2020-218870. \u00a0<\/p>\n<p><sup>7.\u00a0 <\/sup>Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.\u00a0<i>The Lancet<\/i>. 2021;397(10290):2151-2168. doi:10.1016\/S0140-6736(21)00588-2. \u00a0<\/p>\n<p><sup>8.\u00a0 <\/sup>Van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial.\u00a0<i>Lancet<\/i>. 2019;394(10214):2108-2117. doi:10.1016\/S0140-6736(19)32534-6.\u00a0<\/p>\n<p><sup>9.\u00a0 <\/sup><i>A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants with Moderately to Severely Active Ulcerative Colitis<\/i>. clinicaltrials.gov; 2022. Available at:\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3873958-1&amp;h=2175611590&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3817007-1%26h%3D647631714%26u%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT03653026%26a%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT03653026&amp;a=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03653026\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03653026<\/a><\/u>. Accessed\u00a0August 26, 2022.<\/p>\n<p><sup>10.\u00a0 <\/sup><i>A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants with Moderately to Severely Active Ulcerative Colitis (UC)<\/i>. clinicaltrials.gov; 2022. Dispon\u00edbel em:\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3873958-1&amp;h=1818484539&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3817007-1%26h%3D4253986769%26u%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT02819635%26a%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT02819635&amp;a=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02819635\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02819635<\/a><\/u>.\u00a0Acessado em 26 de <span class=\"xn-person\">Agosto de<\/span> 2022.<\/p>\n<p><sup>11.\u00a0 <\/sup><i>A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects with Takayasu Arteritis (TAK) (SELECT-TAK)<\/i>. clinicaltrials.gov; 2021. Dispon\u00edvel em:\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3873958-1&amp;h=2718291851&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3817007-1%26h%3D594391951%26u%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT04161898%26a%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT04161898&amp;a=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04161898\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04161898<\/a><\/u>. Acessado em 26 de <span class=\"xn-person\">Agosto de<\/span> 2022.<\/p>\n<p><sup>12.\u00a0 <\/sup><i>A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants with Axial Spondyloarthritis<\/i>. clinicaltrials.gov; 2021. Dispon\u00edvel em:\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3873958-1&amp;h=3067460567&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3817007-1%26h%3D2451733410%26u%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT04169373%26a%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT04169373&amp;a=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04169373\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04169373<\/a><\/u>. Acessado em 26 de <span class=\"xn-person\">Agosto de<\/span> 2022.<\/p>\n<p><sup>13.\u00a0 <\/sup>Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.\u00a0<i>Lancet<\/i>. 2018;391(10139):2503-2512. doi:10.1016\/S0140-6736(18)31115-2. \u00a0<\/p>\n<p><sup>14.\u00a0 <\/sup>Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.\u00a0<i>Ann Rheum Dis<\/i>. Published online\u00a0October 28, 2020:annrheumdis-2020-218510. doi:10.1136\/annrheumdis-2020-218510. \u00a0<\/p>\n<p><sup>15.\u00a0 <\/sup><i>A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants with Giant Cell Arteritis<\/i>. clinicaltrials.gov; 2022. Dispon\u00edvel em:\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3873958-1&amp;h=1233550970&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3817007-1%26h%3D3334549035%26u%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT03725202%26a%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT03725202&amp;a=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03725202\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03725202<\/a><\/u>. Acessado em 26 de <span class=\"xn-person\">Agosto de<\/span> 2022.<\/p>\n<p><sup>16.\u00a0 <\/sup><i>A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants with Crohn&#8217;s Disease Who Completed the Studies M14-431 or M14-433<\/i>. clinicaltrials.gov; 2022. Dispon\u00edvel em:\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3873958-1&amp;h=88563803&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3817007-1%26h%3D410905107%26u%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT03345823%26a%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fct2%252Fshow%252FNCT03345823&amp;a=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03345823\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03345823<\/a><\/u>. Acessado em 26 de <span class=\"xn-person\">Agosto de<\/span> 2022.<\/p>\n<p><sup>17.\u00a0 <\/sup>Adalimumabe [Resumo das caracter\u00edsticas na Europa]. AbbVie Ltd.; Disponivel em <a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000481\/WC500050870.pdf\" target=\"_blank\" rel=\"nofollow noopener\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000481\/WC500050870.pdf<\/a>.<\/p>\n<p><sup>18.\u00a0<\/sup> <i>Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)<\/i>. Clinicaltrials.gov; 2023. Dispon\u00edvel em\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3873958-1&amp;h=1516776886&amp;u=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT05843643&amp;a=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT05843643\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05843643<\/a><\/u>. \u00a0Acessado em 15 de maio de 2023<\/p>\n<p>\u00a0BR-IMM-230013<\/p>\n<p>\u00a0<\/p>\n<p>FONTE  AbbVie Brasil<\/p>\n<\/div>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PT15688&amp;Transmission_Id=202305310921PR_NEWS_LATAM____PT15688&amp;DateId=20230531\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n<p>A <b>OESP<\/b> n\u00e3o \u00e9(s\u00e3o) respons\u00e1vel(is) por erros, incorre\u00e7\u00f5es, atrasos ou quaisquer decis\u00f5es tomadas por seus clientes com base nos Conte\u00fados ora disponibilizados, bem como tais Conte\u00fados n\u00e3o representam a opini\u00e3o da <b>OESP<\/b> e s\u00e3o de inteira responsabilidade da <b>PR Newswire Ltda<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"PR NEWSWIRE S\u00c3O PAULO, 31 de maio de 2023 \/PRNewswire\/ &#8212;\u00a0A AbbVie (NYSE: ABBV) anunciou que ser\u00e3o apresentados novos dados de longo prazo que mostram o perfil de efic\u00e1cia e de seguran\u00e7a de","protected":false},"author":1,"featured_media":66889,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[31],"tags":[],"class_list":["post-66888","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-prnewsinternacional"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Congresso EULAR 2023: AbbVie apresenta dados de longo prazo que confirmam perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe em diferentes doen\u00e7as reum\u00e1ticas - Ag\u00eancia de Comunica\u00e7\u00e3o<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Congresso EULAR 2023: AbbVie apresenta dados de longo prazo que confirmam perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe em diferentes doen\u00e7as reum\u00e1ticas - Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"og:description\" content=\"PR NEWSWIRE S\u00c3O PAULO, 31 de maio de 2023 \/PRNewswire\/ &#8212;\u00a0A AbbVie (NYSE: ABBV) anunciou que ser\u00e3o apresentados novos dados de longo prazo que mostram o perfil de efic\u00e1cia e de seguran\u00e7a de\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/\" \/>\n<meta property=\"og:site_name\" content=\"Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-31T13:27:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2019\/12\/medialabimagem.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"patric_oliveira\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"patric_oliveira\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/\"},\"author\":{\"name\":\"patric_oliveira\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"headline\":\"Congresso EULAR 2023: AbbVie apresenta dados de longo prazo que confirmam perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe em diferentes doen\u00e7as reum\u00e1ticas\",\"datePublished\":\"2023-05-31T13:27:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/\"},\"wordCount\":1403,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/medialabimagem.png\",\"articleSection\":[\"PR Newswire Internacional\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/\",\"name\":\"Congresso EULAR 2023: AbbVie apresenta dados de longo prazo que confirmam perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe em diferentes doen\u00e7as reum\u00e1ticas - Ag\u00eancia de Comunica\u00e7\u00e3o\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/medialabimagem.png\",\"datePublished\":\"2023-05-31T13:27:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/#primaryimage\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/medialabimagem.png\",\"contentUrl\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/medialabimagem.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewsinternacional\\\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Congresso EULAR 2023: AbbVie apresenta dados de longo prazo que confirmam perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe em diferentes doen\u00e7as reum\u00e1ticas\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\",\"name\":\"Ag\u00eancia de Comunica\u00e7\u00e3o\",\"description\":\"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\",\"name\":\"patric_oliveira\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"caption\":\"patric_oliveira\"},\"sameAs\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"],\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/author\\\/patric_oliveira\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Congresso EULAR 2023: AbbVie apresenta dados de longo prazo que confirmam perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe em diferentes doen\u00e7as reum\u00e1ticas - Ag\u00eancia de Comunica\u00e7\u00e3o","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/","og_locale":"pt_BR","og_type":"article","og_title":"Congresso EULAR 2023: AbbVie apresenta dados de longo prazo que confirmam perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe em diferentes doen\u00e7as reum\u00e1ticas - Ag\u00eancia de Comunica\u00e7\u00e3o","og_description":"PR NEWSWIRE S\u00c3O PAULO, 31 de maio de 2023 \/PRNewswire\/ &#8212;\u00a0A AbbVie (NYSE: ABBV) anunciou que ser\u00e3o apresentados novos dados de longo prazo que mostram o perfil de efic\u00e1cia e de seguran\u00e7a de","og_url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/","og_site_name":"Ag\u00eancia de Comunica\u00e7\u00e3o","article_published_time":"2023-05-31T13:27:00+00:00","og_image":[{"url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2019\/12\/medialabimagem.png","width":1,"height":1,"type":"image\/png"}],"author":"patric_oliveira","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"patric_oliveira","Est. tempo de leitura":"7 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/#article","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/"},"author":{"name":"patric_oliveira","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"headline":"Congresso EULAR 2023: AbbVie apresenta dados de longo prazo que confirmam perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe em diferentes doen\u00e7as reum\u00e1ticas","datePublished":"2023-05-31T13:27:00+00:00","mainEntityOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/"},"wordCount":1403,"commentCount":0,"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/#primaryimage"},"thumbnailUrl":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2019\/12\/medialabimagem.png","articleSection":["PR Newswire Internacional"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/","name":"Congresso EULAR 2023: AbbVie apresenta dados de longo prazo que confirmam perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe em diferentes doen\u00e7as reum\u00e1ticas - Ag\u00eancia de Comunica\u00e7\u00e3o","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/#primaryimage"},"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/#primaryimage"},"thumbnailUrl":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2019\/12\/medialabimagem.png","datePublished":"2023-05-31T13:27:00+00:00","author":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"breadcrumb":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/#primaryimage","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2019\/12\/medialabimagem.png","contentUrl":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2019\/12\/medialabimagem.png"},{"@type":"BreadcrumbList","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewsinternacional\/congresso-eular-2023-abbvie-apresenta-dados-de-longo-prazo-que-confirmam-perfil-de-eficacia-e-de-seguranca-de-upadacitinibe-em-diferentes-doencas-reumaticas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"},{"@type":"ListItem","position":2,"name":"Congresso EULAR 2023: AbbVie apresenta dados de longo prazo que confirmam perfil de efic\u00e1cia e de seguran\u00e7a de upadacitinibe em diferentes doen\u00e7as reum\u00e1ticas"}]},{"@type":"WebSite","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/","name":"Ag\u00eancia de Comunica\u00e7\u00e3o","description":"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37","name":"patric_oliveira","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","caption":"patric_oliveira"},"sameAs":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"],"url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/author\/patric_oliveira\/"}]}},"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/66888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=66888"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/66888\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media\/66889"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=66888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=66888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=66888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}